Table 3

Immunohistochemical staining for P glycoprotein (Pgp)

Control*MDR1 +8 T>C†MDR1 IVS1−81 del G‡MSI-H§
Pgp expressionNormal mucosa (n=14)Tumour (n=14)Normal mucosa (n=11)Tumour (n=11)Normal mucosa (n=17)Tumour (n=17)Normal mucosa (n=12)Tumour (n=12)
*Colorectal cancer (CRC) patients with microsatellite stable tumours and without germline functional MDR1 polymorphisms were used as a control group.
†CRC patients with germline MDR1 promoter polymorphism (+8T>C).
‡CRC patients with germline MDR1 functional polymorphism in intron 1 (IVS81 delG).
§CRC patients with tumours exhibiting high microsatellite instability (MSI-H).
¶No of well differentiated tumours, No of moderately differentiated tumours, No of poorly differentiated tumours.
Low3 (21%)1 (7%) (0,0,1)¶3 (27%)2 (18%) (0,1,1)¶7 (41%)2 (12%) (0,0,2)¶4 (33%)6 (50%) (0,0,6)¶
Moderate4 (29%)6 (43%) (1,5,0)6 (55%)4 (36%) (1,3,0)7 (41%)8 (47%) (2,6,0)4 (33%)1 (9%) (0,1,0)
High7 (50%)7 (50%) (3,4,0)2 (18%)5 (46%) (2,3,0)3 (18%)7 (41%) (3,4,0)4 (33%)5 (40%) (1,4,0)
All 54 (13,31,10)¶1414 (4,9,1)1111 (3,7,1)1717 (5,10,2)1212 (1,5,6)